[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644538":3},{"organization":4,"outcomesModule":7,"designInfo":48,"detailedDescription":47,"studyPopulation":47,"armGroups":54,"interventions":65,"overallOfficials":47,"centralContacts":71,"locations":47,"responsibleParty":77,"collaborators":47,"id":81,"slug":47,"hasResults":82,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":82,"sex":88,"minAge":89,"maxAge":47,"enrollmentInfo":90,"targetDuration":47,"studyType":93,"phases":94,"briefSummary":96,"conditions":97,"keywords":47,"overallStatus":99,"whyStopped":47,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":47},{"fullName":5,"class":6},"Herlev Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":47},[9],{"measure":10,"description":11,"timeFrame":12},"inflammation 6 months","To evaluate the difference between the groups in plasma concentrations of IL-6 during the first 6-months. Endpoints: Plasma concentration of IL-6 (pg\u002Fml) from baseline to 6 months","6 months",[14,18,20,22,24,28,32,36,38,41,44],{"measure":15,"description":16,"timeFrame":17},"Blood samples indicating metabolic status and risk factors","Between group difference in change in triglycerids (mmol\u002FL)","3 month, 6 month, 12 month",{"measure":15,"description":19,"timeFrame":17},"Between group difference in change in cholesterol (mmol\u002FL)",{"measure":15,"description":21,"timeFrame":17},"Between group difference in change in HbA1c (mmol\u002Fmol)",{"measure":15,"description":23,"timeFrame":17},"Between group difference in change in albumin corrected zinc (μmol\u002FL).",{"measure":25,"description":26,"timeFrame":27},"Patient reported Outcomes","Between group difference in change in Quality of life measured with EQ5D, and selfreported infections assessed with a homemaid, not validated questionnare.","3,6, and 12 months",{"measure":29,"description":30,"timeFrame":31},"Bodycomposition","between group difference in change in fat mass (kg) and muscle mass (kg) assessed with Bioimpedance analysis- BIA meassured at Baseline and after 3, 6 and 12 months","3, 6, and 12 months",{"measure":33,"description":34,"timeFrame":35},"Physical performance","between group difference in change in chair stand test 30second","3,6, and 12 month",{"measure":33,"description":37,"timeFrame":35},"between group difference in change in handgrip strength (kg)",{"measure":39,"description":40,"timeFrame":27},"Nutrition and zinc intake","estimating zinc intake using 24 hour recall assessment of nutritional intake. Assessing nutritional status with the Patient Generated Subjective Global Assessment (PG-SGA)",{"measure":42,"description":43,"timeFrame":31},"Inflammation changes at 12 months","Between group difference in change in IL6 (pg\u002Fml), IL8 (pg\u002Fml), YKL-40 (pg\u002Fml)\n\n(IL6 at 6 months are primary outcomes)",{"measure":45,"description":46,"timeFrame":31},"Methods for assessing zinc: Free zinc binding capacity(μmol\u002FL) vs. plasma zinc(μmol\u002FL) (with and without adjustments for albumin)","Evaluating the best way to assess zinc status in humans, and the association to occurring infections and readmissions",null,{"allocation":49,"interventionModel":50,"interventionModelDescription":47,"primaryPurpose":51,"observationalModel":47,"timePerspective":47,"maskingInfo":52},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":53,"maskingDescription":47,"whoMasked":47},"NONE",[55,59],{"label":56,"type":57,"description":58,"interventionNames":47},"Controlgroup","NO_INTERVENTION","Standard treatment",{"label":60,"type":61,"description":62,"interventionNames":63},"Intervention","ACTIVE_COMPARATOR","22 mg zinc supplementation daily for 12 months",[64],"Dietary Supplement: Zinc Supplement",[66],{"type":67,"name":68,"description":69,"armGroupLabels":70,"otherNames":47},"DIETARY_SUPPLEMENT","Zinc Supplement","22 mg Zinc supplementation daily for 12 months",[60],[72],{"name":73,"role":74,"phone":75,"phoneExt":47,"email":76},"Cecilia M Lund, MD, PhD","CONTACT","+4538686112","cecilia.margareta.lund.01@regionh.dk",{"type":78,"investigatorFullName":79,"investigatorTitle":80,"investigatorAffiliation":5,"oldNameTitle":47,"oldOrganization":47},"PRINCIPAL_INVESTIGATOR","Cecilia Margareta Lund","Associate Professor","100644538",false,"NCT07672132","Zinc Supplementation and Inflammation in Older Medical Patients","ZOOM IN Study: Micronutrient Deficiencies and Effect of Zinc Supplementation on Inflammation and Occurrence of Infections in Older Medical Patients (ZOOM) - A Sub-study of a Cluster Randomized Trial","ZOOM-IN","Inclusion Criteria:\n\n* above 65 years old included in ZOOM out ( clinical trials no: NCT07367412)\n* admittet at the medical emergency department Herlev Hospital\n\nExclusion Criteria:\n\n* Patients receiving zinc supplements (\\>10 mg daily) at time of inclusion\n* Patients with terminal illness (life expectancy \\\u003C 6 months, estimated by Clinical Frailty Scale ≥8)\n* Patients receiving parenteral nutrition (partial or complete)\n* Patients treated with hemodialysis or peritoneal dialysis\n* Patients known with severe dementia\n* Patients who do not understand Danish and patients with temporary civil person registration numbers (CPR)","ALL","65 Years",{"count":91,"type":92},220,"ESTIMATED","INTERVENTIONAL",[95],"NA","The hypothesis is that a daily supplement of 22 mg of zinc over 12 months can reduce in-flammatory biomarkers in acutely hospitalized older adults aged ≥ 65 years.\n\nThe aims are to determine, in acutely hospitalized older adults aged ≥ 65 years, if a daily supplement of 22 mg of zinc over 12 months compared to control can decrease inflammato-ry biomarkers, reduce symptoms of self-reported infection, reduce readmission and mortali-ty, increase QoL, increase physical performance, investigate potential adverse events to zinc supplement, and the changes in inflammatory biomarkers. It will also be studied if albumin-corrected zinc in plasma is a more accurate method for assessing zinc status than ordinary plasma zinc.",[98],"Older Medical Patients","NOT_YET_RECRUITING","2026-06-23",{"date":102,"type":103},"2026-06-26","ACTUAL",{"date":105,"type":92},"2026-06-02",{"date":107,"type":92},"2028-05-31",{"name":5,"class":6}]